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Cranial radiationAbstract Background: Treatment of epilepsy with antiepileptic drugs (AED) is effective and
remains the principal mode of management. A group of adverse effects and drug toxicity can
develop immediately or later in the course of treatment. AEDs also have the potential of precipi-
tating idiosyncratic adverse effects including serious cutaneous, hematological and hepatic events.
Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but severe cutane-
ous adverse reactions are related to or caused by a variety of medications including AEDs, they
carry a high mortality and morbidity rate, accurate diagnosis and rapid treatment may improve
the prognosis.
Objective: To characterize the clinical features and methods of differentiating Stevens–Johnson
syndrome from toxic epidermal necrolysis using a case study and to identify other factors that may
contribute to this critical illness.
Conclusion: Clinical knowledge of potential sever adverse reaction of AEDs is essential and may
overcome treatment failure with major impact on health-related quality of life in people with epi-
lepsy.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.77; fax:
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Figure 1.2 Vesicular rash with bullae started to slough leaving
areas of exposed skin surface.
382 K. AlQuliti et al.1. Introduction
Antiepileptic drugs (AED) are known for a variety of adverse
reactions. Stevens–Johnson syndrome and toxic epidermal
necrolysis (SJS, TEN) are among the severe cutaneous drug
reactions reported in the literature that can be initiated by dif-
ferent classes of anticonvulsants, especially in the background
of other high-risk factors such as advanced age, malignancy or
radiation exposure. Prescribing such medications should be
done with caution, especially if the underlying medical condi-
tion could increase the risk of developing SJS–TEN.
2. Case presentation
A 45-year-old female presented to the emergency department
with progressive non-pruritic macular rash. The rash started
on her face and over 3 days spread in a caudal direction to in-
volve her entire body, sparing her legs below the knee (and
affecting more than 80% of total body surface area). The rash
was vesicular with large bullae on the face and swollen eyes
and lips. It was associated with photophobia, a burning sensa-
tion in the eyes and visual impairment, dysphagia, dyspnea,
and dysuria. These symptoms preceded for 2 weeks duration
with prodromal manifestations of fever, malaise, and sore
throat.
The patient had been on phenytoin treatment (100 mg tid)
for 1 month prior to developing this rash, as a management
of secondary partial seizures. She had been diagnosed with
brain metastases secondary to breast cancer 2 months earlier
and received cranial radiotherapy. The right breast cancer
was diagnosed 18 months prior to brain metastases. At that
time management included modiﬁed radical mastectomy of
the right breast followed by 25 sessions of chemo-radiotherapy
and tamoxifen hormonal therapy.
In addition to the phenytoin therapy, the patient was on
dexamethasone (4 mg bid) and ranitidine (150 mg tid). On
admission, physical examination revealed a toxically ill and
distressed patient with a temperature of 38.7 C, pulse rate
of 128 beats per minute, blood pressure of 93/57 mmHg and
respiratory rate of 18 breaths per minute. Skin examination
showed discrete irregular vesicular rash with multiple large
bullae on the face extending to the trunk and down to theFigure 1.1 Left lower limb showed irregular vesicular rash with
multiple large bullae.knees with a positive Nikolsky’s sign. On the third day of
admission, bullae started to slough leaving areas of exposed
skin surface (Figs. 1.1 and 1.2). She had edematous lips with
necrotic mucus membranes and oral ulcerations. Eyes were
also edematous with mucoid discharge. Chest examination
showed that the mastectomized right breast scar was hyperpig-
mented but clear with no evidence of chest wall recurrence.
The other breast was normal. Lungs were clear bilaterally with
no localizing signs, heart with regular rhythm and no added
sounds or gallop rhythm; abdomen was soft, benign with no
tenderness or acute ﬁndings. No peripheral edema. The neuro-
logical exam was unremarkable.
Initial laboratory tests showed a normal white blood cell
count and differential, hemoglobin level and platelet count.
Serum liver enzymes were abnormal with slightly elevated ala-
nine aminotransferase (81 IU/L) and aspartate aminotransfer-
ase (62 IU/L), alkaline phosphatase (71 IU/L), and gamma
glutamyl transpeptidase (624 IU/L). Total bilirubin wasFigure 2.1 (Microscopic description) Section shows epidermal
spongiosis, and basal cell hydropic degeneration. Scattered dys-
keratotic cells are seen. Mild lymphocytic inﬁltration of the
dermo-epidermal junction is also identiﬁed. The upper dermis
shows mild edematous change and mild lymphocytic inﬁltration.
The capillary lumina contain neutrophils. No bullae formation is
identiﬁed.
Figure 2.2 (Magniﬁed) Section shows epidermal spongiosis, and
basal cell hydropic degeneration. Scattered dyskeratotic cells are
seen. Mild lymphocytic inﬁltration of the dermo-epidermal junc-
tion is also identiﬁed. The upper dermis shows mild edematous
change and mild lymphocytic inﬁltration. The capillary lumina
contain neutrophils. No bullae formation is identiﬁed.
Antiepileptic drugs toxicity 3837.9 umol/L, total protein 49 g/L, and albumin 22 g/L. Lactate
dehydrogenase level was 323 IU/L. Renal function test and
serum electrolytes values were normal, i.e., the urea level was
2.8 mmol/L, HCO3 23 mmol/L and blood glucose level
131 mg/dL. Phenytoin level was 19.5 mg/L. The blood culture
revealed gram positive coccemia. There were no signs of phe-
nytoin hypersensitivity syndrome. Skin biopsy was done.
Figs. 2.1 and 2.2 depicts the main histopathological changes.
Early on the clinical impression was SJS–TEN with septice-
mia. The patient was admitted to the intensive care unit and
the critical care team, as well as dermatology and ophthalmol-
ogy, were involved in the patient’s management from the start,
phenytoin was discontinued immediately, The patient was gi-
ven aggressive intravenous ﬂuid management, remained in
the ICU due to hemodynamic instability (BP: 80/50, PR:
140). She continued to be managed with vigorous IV ﬂuids
and inotropic agents hydrocortisone 100 mg IV Q8H, pipera-
cillin–tazobactam 4.5 gm IV Q6H and vancomycin 1 gm IV
were administered. Additional therapies included oﬂoxacin
eye drops, itraconazole mouth gel, pantoprazole 40 mg IV
Q24H and prophylactic dose of enoxaparin 40 mg daily SQ.
Intensive skin care was practiced and dressings were applied.
After 2 days in the ICU, the patient showed normalized tem-
perature, but remained dependent on inotropes with deterio-
rating general condition despite intense medical support and
mechanical ventilation support. She manifested repeated epi-
sodes of hemodymanic instability until she died on the 11th
day of hospitalization.
3. Discussion
Stevens–Johnson syndrome (SJS) and toxic epidermal necroly-
sis (TEN) are severe adverse drug reactions, characterized by
low incidence but high mortality. Studies of incidence of SJS
and TEN reveal that they are rare diseases with 1–7.1 and
0.4–1.4 cases per million per year in the general population,
respectively. The difference in the clinical picture is quantita-tive: SJS represents cases of less than 10% total body surface
area (TBSA) involved; TEN indicates more than 30%; and
those in-between are labeled SJS–TEN ‘‘overlap’’. Another
important difference between SJS and TEN is the rate of mor-
tality: in SJS it varies from 1% to 5%, in TEN from 25% to
50%. Outcome is difﬁcult to predict. Increasing age, signiﬁcant
comorbidities and a greater extent of skin involvement corre-
late with a worse prognosis (Lissia et al., 2009). Bastuji-Garin
et al. validated a speciﬁc TEN severity-of-illness scale (SCOR-
TEN) as a useful method to predict mortality in TEN patients.
SCORTEN analyzes seven independent risk factors: (1)
age > 40 years; (2) TBSA involved > 10%; (3) serum urea le-
vel > 28 mg/dl; (4) glucose level > 252 mg/dl; (5) bicarbonate
level < 20 mEq/l; (6) heart rate > 120 beats per minute; (7)
presence of cancer/hematologic malignancies. One point is as-
signed to each risk factor if positive and zero points if negative,
with the total representing the ﬁnal score. A score of 0–1 has
an expected mortality of 3.2%; when the score is 2 the mortal-
ity rises to 12.2%. It reaches 35.3% and 58.3% when the score
is 3 and 4, respectively. Expected mortality is 90% when the
score is 5 or more (Bastuji-Garin et al., 2000). Our presented
case had multiple risk factors, which made her prognosis very
poor. According to the SCORTEN scale, she had a total of 4
positive factors (age > 40, TBSA involved > 10%, HR> 100
and malignancy), corresponding to 58.3% mortality rate.
Drugs have been the most incriminating contributor to the
etiology of SJS–TEN, of which anticonvulsants such as phe-
nytoin, carbamazapine, and phenobarbitol are the most com-
monly implicated. In addition, allopurinol, NSAIDs,
corticosteroids and different classes of antibiotics, such as sul-
fonamides (particularly trimethoprim/sulfamethoxazole), b-
lactam, tetracyclines and quinolones (especially ciproﬂoxacin),
were also found to have a role. The correlation between TEN
and drug intake is based on clinical recognition and usually
develops 1–3 weeks after the administration of the suspect
drug. Radiation therapy is another contributory factor (Rou-
jeau et al., 1995; Borchers et al., 2008). Our patient developed
symptoms of TEN after 1 month of phenytoin administration
and after exposure to cranial radiation.
In 2004, Ahmed et al. reviewed the literature of all pub-
lished similar cases. They concluded that the need for prophy-
lactic anticonvulsant therapy, especially phenytoin in patients
undergoing cranial radiotherapy, should be assessed on a
case-by-case basis, stressing phenytoin should be administered
with caution and good follow-up (Ahmed et al., 2004).
Diagnosis of the disease is made histologically by skin
biopsy (Lissia et al., 2009). The condition usually is preceded
by a prodromal phase, which frequently consists of inﬂu-
enza-like symptoms, including fever, cough, myalgias, arthral-
gias, and malaise, which may last from 1 day to 2 weeks. This
is followed by the appearance of skin lesions, mostly on the
trunk and face, but can also occur on the neck and proximal
extremities. The characteristic skin lesions are ﬂat, irregular,
atypical target lesions or diffuse purpuric macules that fre-
quently have necrotic centers (particularly in TEN), and tend
to coalesce over the course of time. Lesions can express a po-
sitive Nikolsky’s sign (lateral displacement of the necrotic epi-
dermis in response to slight pressure). In almost 90% of
patients, the mucous membranes are affected; ocular involve-
ment is seen in approximately 60% of patients. Buccal, bron-
chial, gastrointestinal and anogenital mucosa also have been
involved (Borchers et al., 2008). Septicemia is the most
384 K. AlQuliti et al.frequent cause of death in patients with TEN and is usually
due to Staphylococcus aureus or pseudomonas (Atiyeh et al.,
2003). The patient in this case study developed the full spec-
trum of the disease with involvement of all mucus membranes.
Her blood culture showed gram positive cocci septicemia
which could have added to the poor prognosis.
Optimal treatment of SJS and TEN involves a multi-
pronged, multidisciplinary approach to address the removal
of the inciting agent(s), maintaining ﬂuid and temperature
homeostasis, treating multi-organ damage, and preventing fur-
ther systemic complications (Borchers et al., 2008). Since med-
ications are the most common cause of TEN, and most likely
SJS as well, it is imperative to take an extensive history to
determine and then discontinue all potential causative medica-
tions. Prompt withdrawal of the culprit drug is associated with
a decreased mortality risk, though immediate results after ces-
sation are not always noted. Supportive therapy is similar to
treatment for burn patients, preferably in burn center. Treat-
ment strategies therefore are aimed at providing thermoregula-
tion, ﬂuids and electrolytes, and parenteral nutrition when
necessary. In addition, it is imperative to monitor closely for
infection to prevent sepsis. If there is pulmonary involvement,
mechanical ventilation may be required to correct acute hyp-
oxemia, though in less severe situations, nebulized saline,
bronchodilators, and physiotherapy can assist in overcoming
damage to respiratory epithelium (Abood et al., 2008). Given
the majority of patients have ocular involvement, an ophthal-
mologist should assess and minimize the risk of eye damage
with treatments including topical lubricants/antibiotics and
steroid drops (Borchers et al., 2008; Roujeau and Stern,
1994; astuji-Garin S, 1993). In a 2008 study, Schneck et al.
found no sufﬁcient evidence of a beneﬁt for any speciﬁc treat-
ment including corticosteroids, immunosuppressants (cyclo-
phosphamide, cyclosporin), antitumor necrosis factor-alpha
agents, plasmapheresis and intravenous immunoglobulin
(IVIG) Schneck et al., 2008. The utility of IVIG treatment re-
mains controversial. The lack of controlled, randomized, com-
parative trials leaves the debate open.
4. Conclusion
Patients on the phenytoin therapy or other medications which
could induce SJS–TEN should be closely followed, especiallyin the context of underlying malignancy and radiation expo-
sure which might potentiate the toxic adverse reactions of
these medications. In addition, patients should be warned
about the potential side effects of such medications and to seek
medical evaluation if they develop any of these side effects,
especially cutaneous reactions. Any of these side effects should
be taken seriously with thorough physical examination and
high index of suspicion for SJS–TEN.
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